Extravasation of therapeutic 90 Y-ibritumomab tiuxetan can cause significant injury. Detection of extravasated 90 Y using a g-camera for patients undergoing 90 Y-ibritumomab tiuxetan therapy is a challenge because of the inherently low efficiency of bremsstrahlung imaging and the interference of prompt and scattered photons from 111 In that are still present in the body at the time of 90 Y injection. We have configured a g-camera to image bremsstrahlung radiation from superficial 90 Y in the presence of 111 In and evaluated the effectiveness using phantoms. Methods: Phantoms were constructed to contain 90 Y and 111 In with activity levels and with a geometry approximating conditions in a patient being scanned for evaluation of possible extravasation in the antecubital fossa. Imaging was performed using a camera equipped with medium-energy general-purpose (MEGP) and high-energy general-purpose (HEGP) collimators. Results: The contrast that developed between the patch representing extravasated solution and the background was comparable for MEGP and HEGP collimators. With MEGP collimators and 5-min acquisitions, a patch containing 8.3 MBq (220 mCi) distributed over an elliptic area of 7 · 11 cm was clearly discernable. Conclusion: With our experimental arrangement, the lower limit of detection is approximately 8 MBq. We calculate that an extravasation of this much 90 Y would result in an absorbed dose to the skin and subcutaneous tissue of 2.5 Gy, which is close to the threshold for skin damage. This technique is therefore sensitive enough to be of use in the clinic when extravasation of 90 Y is suspected. Radi oimmunotherapy is a cancer treatment modality that has grown in importance over the past decade. The combination of monoclonal antibodies and short-range radioisotopes is designed to deliver a localized radiation dose to specific targets. Used primarily in the treatment of lowgrade, non-Hodgkin lymphoma, radioimmunotherapy with 90 Y-ibritumomab tiuxetan (Zevalin; Biogen-Idec) is approved both for first-line therapy and for relapsed or recurrent lymphoma.
Radi oimmunotherapy is a cancer treatment modality that has grown in importance over the past decade. The combination of monoclonal antibodies and short-range radioisotopes is designed to deliver a localized radiation dose to specific targets. Used primarily in the treatment of lowgrade, non-Hodgkin lymphoma, radioimmunotherapy with 90 Y-ibritumomab tiuxetan (Zevalin; Biogen-Idec) is approved both for first-line therapy and for relapsed or recurrent lymphoma.
The potential for complications arising from extravasation of chemotherapeutics is well understood by medical oncologists (1) . Extravasation is estimated to occur in 0.6%-6% of administrations (2) . In the field of nuclear medicine however, there appears to be relatively few reports of side effects caused by extravasation of radiotherapeutic agents, and the expectation and degree of vigilance for this type of reaction are generally low. The dearth of reported tissue reactions related to the administration of therapeutic agents containing 32 P, 153 Sm, 89 Sr, or 186 Re may be attributable to the short residence times due to the rapid reabsorption of those agents. In the case of 90 Y-ibritumomab tiuxetan, however, the large molecules could have a relatively slow clearance rate and thus pose a greater risk for radiation injury in the event of extravasation.
We previously reported on a case of radiation injury that occurred in our clinic (3) . It was estimated that extravasation of between 68 and 136 MBq of 90 Y occurred in the antecubital fossa, resulting in an estimated absorbed dose of 20-40 Gy (3). An area of erythema was noted as soon as the following day and subsequently progressed to an 8 · 11 cm elliptic region of grade 3 dermatitis (wet desquamation).
The 90 Y-ibritumomab tiuxetan protocol prescribes an initial injection of 111 In-labled ibritumomab tiuxetan followed by imaging at 48-72 h. Provided a favorable biodistribution is observed, the patient receives the therapeutic infusion of 90 Y-labeled ibritumomab tiuxetan on day 7. 90 Y is a pure b-emitter, and imaging is challenging because of the absence of prompt g-emission. Strategies for imaging distributions of 90 Y by detecting bremsstrahlung emissions have been used for various applications (4, 5) , but in this case, the g-radiation from the 111 In, still present in the body in appreciable amounts, complicates the problem. Bremsstrahlung photons are emitted as the b-particles decelerate in tissue and form a continuous energy spectrum from zero to a maximum of 2.3 MeV-the b-endpoint energy. The efficiency of bremsstrahlung production is low, particularly in the low-Z tissue matrix, so even at low concentrations of 111 In relative to 90 Y, the photopeaks from the 111 In g-emissions at 171 and 245 keV are prominent. A technique designed to detect 90 Y distributions must reject those photons.
MATERIALS AND METHODS

Estimation of Relative Emissions
To establish the relative concentrations of 90 We fortuitously had available an abdominal 111 In SPECT/ CT study obtained just before 90 Y infusion in a 90 Y-ibritumomab tiuxetan patient, that is, 7 d after injection of 111 Inibritumomab tiuxetan. A coronal section through the chest and abdomen is shown in Figure 1 . We observed the activity to be fairly evenly distributed in the arms and throughout the tissues of the body, with the liver having a markedly more intense activity concentration approximately 7:1 relative to the background.
Estimation of Absorbed Dose Due to Extravasation
On the basis of our experience with a single case of skin damage that resulted from extravasation of 90 Y, we estimated the absorbed dose to the skin as follows. The subsequent skin damage at its greatest extent was observed approximately 3 wk later as an elliptic patch measuring 7 · 11 cm. The maximum range of b-particles emitted by 90 Y is 11 mm in tissue, and the average range is 2.5 mm, with the deposited energy distributed along the particle's trajectory. From our observation of tissue damage and from a rough estimate of the depth of infusion plus a margin for b-particle range, we estimated the effective distribution of energy deposition to be an elliptic cylinder 7 · 11 · 1 cm thick, for a total volume of 60 cm 3 , or a total tissue mass of 0.06 kg assuming a tissue density of 1 g/cm 3 . The amount of fluid extravasated into the skin of the antecubital fossa was estimated by the staff to be between 0.5 and 1 mL of the 9-mL injection volume, which corresponds to 68-136 MBq. Based on limited data in the literature (6,7), we assumed a biologic half-life of 36 h for 90 Y-ibritumomab tiuxetan in tissue and thus computed a mean lifetime of 33 h. Using the energy per transition of 1.49 · 10 213 GyÁkg/BqÁs (8), we computed the corresponding absorbed dose to be 20-40 Gy.
Phantom
A phantom arrangement designed to approximate the geometry of a patient undergoing imaging to detect the presence of 90 Y extravasation was assembled from 3 parts: a torso phantom constructed by Data Spectrum Corp. that contains separately fillable lung and liver spaces, a cylindric tube with an inside diameter of 7.6 cm and a length of 38 cm to simulate the arm, and an elliptic 7 · 11 cm patch made from absorbent paper sealed between layers of plastic wrap.
The phantoms were filled with 111 In and 90 Y in amounts chosen to simulate the approximate distribution of 111 In and 90 Y expected on day 8 of the 90 Y-ibritumomab tiuxetan protocol, that is, immediately after infusion of 90 Y. The assumptions were that the liver concentrates activity in a FIGURE 1. Coronal section from 111 In SPECT/CT study showing slice through chest and abdomen of patient 7 d after receiving 111 In injection. Activity is fairly uniform throughout soft tissue but is markedly concentrated in liver. FIGURE 2. Phantom arrangement consisted of torso phantom with lung and liver inserts, and adjacent cylindric arm phantom held in arm rest. The 7 · 11 cm absorbent patch is visible on superior surface of cylinder. ratio of 7:1 but activity elsewhere in the body is distributed uniformly; that the patient weighs 70 kg (volume of 70 L); and that only physical, not biologic, decay of the 185 MBq of 111 In injected on day 1 occurs. We thus filled the torso and arm phantoms with 0.47 and 14.8 kBq/mL activity concentrations of 111 In and 90 Y, respectively, and we filled the liver portion of the torso phantom with 7 times those concentrations.
The patches were prepared by diluting the activity into a volume of 1 mL, which we found by experimentation to be the correct quantity of liquid to just soak the absorbent paper and therefore create an elliptic region of uniform activity. Activities soaked onto the patches were 8.3, 13.7, and 26.9 MBq.
The phantoms were placed on the imaging table to simulate the geometry of a patient lying supine with arms down. The phantom arrangement in place for imaging is shown in Figure 2 .
Planar Imaging
Images were acquired on the ADAC Forte dual-head g-camera using medium-energy general-purpose (MEGP) and high-energy general-purpose (HEGP) collimators. The energy window for bremsstrahlung imaging was centered at 120 keV with a 50% window (90-150 keV). This setting accepts photons between the lead x-ray peak and the 171-keV photopeak from 111 In. This is illustrated in Figure  3 . Images acquired with MEGP collimators had a matrix size of 256 · 256 · 16 and an acquisition duration of 5 min. Images acquired with HEGP collimators had the same matrix size and an acquisition time of 10 min.
RESULTS
Images acquired with both sets of collimators and with the 8.3-and 26.9-MBq patches in place are shown in Figure  4 . The most intense patch is clearly visible in the figure, and the least intense patch is just above the threshold of detection. We placed regions of interest on the images, and the results are graphed in Figures 5A and 5B. One region of interest was centered on the patch, and a background region of interest was placed on the arm phantom, just below the patch. Background counts were approximately 10 counts per pixel for the 5-min acquisition with MEGP collimators and 15 counts per pixel for the 10-min acquisition with HEGP collimators. As the patch activity increases, background counting rate goes up slightly for the images acquired with MEGP collimators and goes up only slightly or not at all for the HEGP collimators.
The contrast was calculated as the difference between average patch and background count densities divided by the background. This is graphed in Figure 5C , and it becomes clear that there is no contrast advantage of the HEGP collimators except perhaps for the highest-intensity patch. 
DISCUSSION
Motivated by our experience of radiation-induced injury caused by extravasation of 90 Y-ibritumomab tiuxetan, we sought to design and evaluate an imaging scheme sensitive enough to detect the bremsstrahlung radiation emitted by 90 Y but insensitive to 111 In g-emission, which forms an appreciable background 7 d after injection. The approach we have taken uses a standard g-camera with MEGP collimators and with the energy window set to detect photons in the range of 90-150 keV. This window overlaps a region of relatively high bremsstrahlung radiation while avoiding lead x-rays on one end and the 171-keV photopeak from 111 In decay on the other end.
Our phantom was designed to mimic, to some degree, the conditions expected 7 d into the 90 Y-ibritumomab tiuxetan protocol, after 90 Y infusion, when a suspected extravasation would be investigated. The concentration and distribution of 111 In and 90 Y were estimated from limited clinical observations, as was the distribution pattern of 90 Y extravasation. With this phantom arrangement, we demonstrated that we could detect extravasation in the area of the antecubital fossa down to an activity of about 8 MBq. Of course in practice, there would be a great deal of variability associated with these conditions, making a precise determination of the limits of detection difficult. In our phantom acquisitions, by arranging the torso next to the arm instead of mimicking an extended arm, and by distributing the 90 Y extravasation over a relatively large area (extravasation might be expected to be initially less dispersed), we have mimicked a worst-case scenario. It may well be possible to detect activity lower than 8 MBq.
Using the same model for the geometry and clearance of extravasation as we used previously, we can calculate that an extravasation of 8 MBq of 90 Y would result in an absorbed dose of 2.4 Gy to the skin and subcutaneous tissue. Thus, we surmise from these estimates that we can image 90 Y, in the presence of residual 111 In, with a lower limit of detection that is close to the threshold for radiation damage. For the lowest activities tested, a MEGP collimator produced at least as great a contrast relative to background in a shorter acquisition time.
CONCLUSION
We have evaluated the ability to imaging bremsstrahlung from 90 Y in the presence of 111 In in a phantom study designed to mimic extravasated 90 Y-ibritumomab tiuxetan immediately after injection. With MEGP collimators and a 5-min acquisition time on a conventional g-camera, extravasation can be detected at the approximate concentration that would be expected to cause skin damage. This technique is therefore sensitive enough to be of use in the clinic when extravasation of 90 Y-ibritumomab tiuxetan is suspected. 
